Carcinoid tumor

This phase II trial tests whether combining the immunotherapy drug nivolumab with the chemotherapy drug temozolomide can shrink tumors in people with small-cell lung cancer that has returned or not responded to treatment, or advanced neuroendocrine tumors. About 55 participants w…

This trial tests whether combining two drugs—RAD001 (everolimus) and octreotide depot—can slow tumor growth in people with advanced low-grade neuroendocrine cancer (carcinoid or islet cell tumors) that has spread or cannot be removed surgically. Participants take RAD001 daily by …

This study looked at 116 people with small-intestine neuroendocrine tumors to see if a blood test or a shorter urine collection could replace the standard 24-hour urine test for diagnosis. The goal was to find a simpler, equally accurate way to measure a key tumor marker called 5…

This Phase 2 trial tested paltusotine, an oral drug, in 36 adults with carcinoid syndrome. The study looked at safety and how the body processes the drug at different doses. Participants were randomly assigned to 40 mg or 80 mg daily, with dose adjustments allowed. The goal is to…

This study looked at nearly 94,000 people diagnosed with gastrointestinal carcinoid tumors between 2000 and 2022. Researchers used a large cancer database to calculate how many patients died from their tumor compared to the general population. The goal was to fill gaps in knowled…

This study looked at nearly 94,000 people with rare gastrointestinal carcinoid tumors to see if early detection has changed over time. Researchers analyzed cancer registry data from 2000 to 2022 to track whether tumors were found at earlier or later stages. The goal was to unders…

This study analyzed data from over 93,000 people diagnosed with a gastrointestinal carcinoid tumor between 2000 and 2022. Researchers wanted to find out if these patients are more likely to develop a second, different gastrointestinal cancer. They used a large cancer database to …